Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now.
On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc. (NASDAQ:VRDN) from $35 to $39, implying an adjusted upside potential in excess of 105% at the prevailing level
The firm maintained its Buy rating on the stock. Mila Supinskaya Glashchenko/ Goldman Sachs reflected on the FDA approval call regarding Viridian’s Lumvoa, which carries a unique profile for the treatment of thyroid eye disease compared to Tepezza. The firm stated that Lumvoa is more efficient for the improvement of proptosis, and its safety profile is promising.
Its dosing regimen is also more convenient, which backs a highly optimistic stance towards its planned commercial launch. On June 30, Truist also increased its target price on the stock from $35 to $38, which yields more than 100% upside potential. The firm reiterated a Buy rating on the stock, also highlighting Lumvoa’s differentiated profile relative to Tepezza.